KalVista Pharmaceuticals (NASDAQ:KALV) Releases Earnings Results, Beats Expectations By $0.04 EPS

KalVista Pharmaceuticals (NASDAQ:KALV) posted its quarterly earnings results on Thursday. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.04, Yahoo Finance reports.

KalVista Pharmaceuticals Price Performance

Shares of KalVista Pharmaceuticals stock opened at $12.87 on Friday. KalVista Pharmaceuticals has a 1 year low of $7.21 and a 1 year high of $16.88. The company has a market capitalization of $542.96 million, a P/E ratio of -3.79 and a beta of 0.91. The business has a 50 day moving average price of $13.16 and a 200 day moving average price of $12.43.

Insider Buying and Selling

In related news, CEO Benjamin L. Palleiko sold 14,215 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $12.01, for a total transaction of $170,722.15. Following the completion of the transaction, the chief executive officer now directly owns 242,527 shares in the company, valued at approximately $2,912,749.27. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Christopher Yea sold 7,102 shares of the business’s stock in a transaction on Monday, August 19th. The shares were sold at an average price of $12.01, for a total transaction of $85,295.02. Following the completion of the sale, the insider now directly owns 84,467 shares of the company’s stock, valued at approximately $1,014,448.67. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Benjamin L. Palleiko sold 14,215 shares of the company’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $12.01, for a total transaction of $170,722.15. Following the sale, the chief executive officer now directly owns 242,527 shares of the company’s stock, valued at $2,912,749.27. The disclosure for this sale can be found here. Insiders sold 23,452 shares of company stock worth $282,491 in the last ninety days. Insiders own 12.30% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday. Cantor Fitzgerald upgraded shares of KalVista Pharmaceuticals to a “strong-buy” rating in a research report on Monday, August 26th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $32.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.